Show simple item record

dc.contributor.authorPors, Klaus*
dc.contributor.authorMoreb, J.S.*
dc.date.accessioned2016-11-23T17:54:33Z
dc.date.available2016-11-23T17:54:33Z
dc.date.issued2014-12
dc.identifier.citationPors K and Moreb JS (2014) Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development? Drug Discovery Today. 19(12): 1953-1963.
dc.identifier.urihttp://hdl.handle.net/10454/10521
dc.descriptionNo
dc.description.abstractAldehyde dehydrogenases (ALDHs) belong to a superfamily of 19 isozymes that are known to participate in many physiologically important biosynthetic processes including detoxification of specific endogenous and exogenous aldehyde substrates. The high expression levels of an emerging number of ALDHs in various cancer tissues suggest that these enzymes have pivotal roles in cancer cell survival and progression. Mapping out the heterogeneity of tumours and their cancer stem cell (CSC) component will be key to successful design of strategies involving therapeutics that are targeted against specific ALDH isozymes. This review summarises recent progress in ALDH-focused cancer research and discovery of small-molecule-based inhibitors.
dc.relation.isreferencedbyhttps://doi.org/10.1016/j.drudis.2014.09.009
dc.subjectAnimals; Antineoplastic agents; Drug discovery; Biomarkers; Humans; Isoenzymes; Antagonists;Neoplasms; Neoplastic stem cells; Aldehyde dehydrogenase
dc.titleAldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development?
dc.status.refereedYes
dc.typeArticle
dc.type.versionNo full-text available in the repository


This item appears in the following Collection(s)

Show simple item record